Author

R. D. Turan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

C. Tastan· 3 shared E. Ovali· 3 shared A. S. Kocagoz· 2 shared B. Yurtsever· 2 shared C. Hemsinlioglu· 2 shared D. Cakirsoy· 2 shared D. Dilek Kancagi· 2 shared D. Telci· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Tastan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Phytohemagglutinin-Activated CAR-T Cells: Prolonged Persistence and Enhanced Anti-Tumor Response in CD19-Specific Acute Lymphoblastic Leukemia

B. Sert, G. Gulden, T. Teymur, Y. Ay, R. D. Turan, O. M. Unaldi, E. Guzenge, H. E. Erdil, S. Isik, P. Oz, I. Bozkurt, T. Arpaci, O. Kamali, E. Ovali, N. Tarhan, C. Tastan

This paper develops and tests two CD19-specific CAR-T cell designs, showing that PHA-activated CAR19BB-T cells provide prolonged persistence and enhanced anti-tumor effects in preclinical models of ALL.

bioRxiv · Jul 15, 2023 · PreprintImmunology

Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice

R. D. Turan, C. Tastan, D. Dilek Kancagi, B. Yurtsever, G. Sir Karakus, S. Ozer, S. Abanuz, D. Cakirsoy, G. Tumentemur, S. Demir, U. Seyis, R. Kuzay, M. Elek, M. E. Kocaoglu, G. Ertop, , E. Ovali

This paper describes an inactivated SARS-CoV-2 vaccine candidate, OZG-38.61.3, that provides protection in human ACE2-transgenic mice through gamma irradiation and intradermal administration.

bioRxiv · Oct 28, 2020Immunology

Preliminary report of preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates, SK-01 version 1 and OZG-3861 version 1

G. SIR KARAKUS, C. Tastan, D. Dilek Kancagi, B. Yurtsever, G. Tumentemur, S. Demir, R. D. Turan, S. Abanuz, D. Cakirsoy, U. Seyis, S. Ozer, O. Elibol, M. Elek, G. Ertop, S. Arbak, , E. Ovali

This study evaluates the safety and immunogenicity of two gamma-irradiated inactivated SARS-CoV-2 vaccines in mice, showing significant antibody and T cell responses without antibody-dependent enhancement.

bioRxiv · Sep 4, 2020 · PreprintImmunology